Quick Links

Accreditation/Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Merck Sharp & Dohme Corp.

Community Practice Connections™: New Frontiers in Immuno-Oncology for Microsatellite Instability-High Cancers

Release Date: August 29, 2017
Expiration Date: August 29, 2018
Media: Internet - based


Activity Overview

Community Practice Connections™: New Frontiers in Immuno-Oncology for Microsatellite-Instability-High Cancers is a continuing medical education (CME)-certified activity based on a symposium of the same name held in Chicago, Illinois, on June 5, 2017.

The significance of deficiencies in mismatch repair (MMR) pathways and microsatellite instability (MSI) toward the delivery of precision cancer care is evolving. MMR deficiencies and MSI are important components in the pathogenesis of certain solid tumors that carry both prognostic and predictive value. Results from clinical studies suggest that a variety of solid tumors that are deficient in MMR (dMMR)/have a MSI-high (MSI-H) phenotype have higher responses to immune checkpoint inhibition than do MMR-proficient tumors, and these findings have prompted further studies in this area. These investigations have already led to the FDA approval of the first tumor location-agnostic indication for a cancer therapy, with immunotherapy now being delivered based on genetic composition (ie, MSI-H) rather than tumor type.

This CME activity consists of a series of brief interviews with 3 expert faculty members exploring clinically relevant questions concerning the use of MSI status from the community physician perspective. We invite you to join these experts as they guide participants through this fascinating and potentially practice-transforming application of immunotherapy. Important topics addressed in this activity include:

  • dMMR/MSI testing considerations and recommendations
  • Potential role of MSI status as a predictive marker in solid tumors
  • Immunogenicity of dMMR/MSI-H tumors
  • Emerging clinical trial data regarding the use of immunotherapy for dMMR/MSI-H tumors

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Merck Sharp & Dohme Corp.

CME Activity Table of Contents

  • Module 1. Overview of Mismatch Repair and Microsatellite Instability Testing
  • Module 2. Response to Immune Checkpoint Inhibition in Gastrointestinal Cancers and Impact of Microsatellite Instability Status
  • Module 3. Expanding Immunotherapy to Microsatellite Instability-High Nongastrointestinal Cancers: Emerging Clinical Data

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists who treat patients with solid tumors. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of solid tumors also are invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Explain the evolving roles for MMR deficiency and MSI testing in clinical oncology practice
  • Describe the relationship between MSI status and immunologic response, including evidence concerning the use of MSI as a predictive marker for response to checkpoint blockade
  • Evaluate current and emerging clinical trial results concerning the use of immunotherapeutic approaches in patients with MSI-H tumors
  • Delineate next steps in the field concerning the use of novel treatment strategies for the management of MSI-H cancers

Faculty, Staff, and Planners' Disclosures

Program Chair

Wells Messersmith, MD, FACP
Professor and Head, Division of Medical Oncology
Director, GI Medical Oncology Program
Co-Leader, Developmental Therapeutics Program
University of Colorado Cancer Center
University of Colorado School of Medicine
Denver, CO

Disclosure: Grant/Research Support: Roche/Genentech, Pfizer, Immunomedics, OncoMed, Alexo; Consultant: Gilead.


Cathy Eng, MD, FACP
Director and Professor
Department of Gastrointestinal Medical Oncology
Associate Medical Director Colorectal Center
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosure: Grant/Research Support: Daiichi, Keryx; Consultant: Bayer, Sirtex; Speakers Bureau: Genentech, Taiho; Other: Honoraria ‒ Roche Genentech, Bayer.

Dung Le, MD
Medical Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University School of Medicine
Bunting-Blaustein Cancer Research Building
Baltimore, MD

Disclosure: Grant/Research Support: Merck, BMS; Consultant: Merck.

Bradley J. Monk, MD, FACS, FACOG
Arizona Oncology (US Oncology Network)
Professor, Gynecologic Oncology: University of Arizona and Creighton University
Phoenix, AZ

Disclosure: Grant/Research Support: Amgen, Genentech, Lilly, Array, TESARO, Morphotek, Janssen/Johnson & Johnson; Consultant: Merck, TESARO, Gradalis, Advaxis. Amgen, Insys, Clovis, Mateon (formerly Oxigene), Roche/Genentech, AstraZeneca, Pfizer, PPD, Precision Oncology, Perthera, Biodesix, ImmunoGen, Cue; Speakers Bureau: Roche/Genentech, AstraZeneca, Janssen/Johnson & Johnson, Clovis, TESARO.

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Become a Member

Forgot Password?
Calendar of Events
Filter By